Douglas House of Seeking Alpha has delivered the n
Post# of 148158
(Total Views: 1018)
Posted On: 09/03/2020 3:39:31 AM
Douglas House of Seeking Alpha has delivered the next chapter in his series of bias-tainted news articles on CytoDyn. He's written dozens of articles on CytoDyn, yet managed to misspell leronlimab in the article's heading:
CytoDyn to discuss accelerated approval of leronlimad for COVID-19 with UK health authorities September 9
"News Editor" Doug is either completely incompetent or just maybe, he has an ulterior motive when reporting on CytoDyn. His mistake was mentioned in the article comments, yet he hasn't corrected the misspelling. See below for the history of Doug's "reporting" on CytoDyn:
-CytoDyn reports "strong results" with leronlimab in COVID-19 (What objective News Editor would use quotation marks around strong results? Seems like a sly attempt to instill fear, uncertainty, and doubt)
-CytoDyn down 9% as CEO moves to sell stock while touting COVID-19 drug (Includes link to AF's stat news article which is inappropriate. This would never pass editorial muster at a serious news institution. He is also implying motive, which makes it subjective in nature)
-CytoDyn down 32% on bearish Citron report (This time he links to Andrew Left's report and relies on it as a legit news source when only hours later, Left himself pulled the story with no explanation)
-FDA rejects CytoDyn's leronlimab application for HIV (Why not say "issued a Refusal to File letter" in the headline as he did in the body of his report? Using "rejects" gives the headline a negative slant)
-CytoDyn announces "positive" results from mid-stage COVID-19 study (See first comment above)
-"clinically significant" (see above - a pattern is emerging here)
-CEO emphasizing the NEWS2 secondary endpoint which was met, not the primary endpoint which was missed. (Misleading in its brevity (clinical significance attained in primary endoint) and also a stupid comment as in who wouldn't emphasize the most positive results?)
-Premature to know if the ongoing Phase 2 in severely and critically ill COVID-19 patients will be a "double, triple or home run." An interim analysis will be conducted after 195 patients have been treated. (Mockery?)
CytoDyn to discuss accelerated approval of leronlimad for COVID-19 with UK health authorities September 9
"News Editor" Doug is either completely incompetent or just maybe, he has an ulterior motive when reporting on CytoDyn. His mistake was mentioned in the article comments, yet he hasn't corrected the misspelling. See below for the history of Doug's "reporting" on CytoDyn:
-CytoDyn reports "strong results" with leronlimab in COVID-19 (What objective News Editor would use quotation marks around strong results? Seems like a sly attempt to instill fear, uncertainty, and doubt)
-CytoDyn down 9% as CEO moves to sell stock while touting COVID-19 drug (Includes link to AF's stat news article which is inappropriate. This would never pass editorial muster at a serious news institution. He is also implying motive, which makes it subjective in nature)
-CytoDyn down 32% on bearish Citron report (This time he links to Andrew Left's report and relies on it as a legit news source when only hours later, Left himself pulled the story with no explanation)
-FDA rejects CytoDyn's leronlimab application for HIV (Why not say "issued a Refusal to File letter" in the headline as he did in the body of his report? Using "rejects" gives the headline a negative slant)
-CytoDyn announces "positive" results from mid-stage COVID-19 study (See first comment above)
-"clinically significant" (see above - a pattern is emerging here)
-CEO emphasizing the NEWS2 secondary endpoint which was met, not the primary endpoint which was missed. (Misleading in its brevity (clinical significance attained in primary endoint) and also a stupid comment as in who wouldn't emphasize the most positive results?)
-Premature to know if the ongoing Phase 2 in severely and critically ill COVID-19 patients will be a "double, triple or home run." An interim analysis will be conducted after 195 patients have been treated. (Mockery?)
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼